Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

Polypeptides

Bivalirudin Acetate 128270-60-0

Bivalirudin Acetate 128270-60-0

98% up by HPLC, Pharma Grade, USP, cGMP, DMF
  • Product Details

Product Information


Product name

Bivalirudin Acetate

CAS No.

128270-60-0

Synonyms

BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;Bivalirudin, TFA;BITTERMELONP.E;Human Bivalirudin;Bivalirudin Acetate;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH;H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH trifluoroacetate salt

Molecular Formula

C98H138N24O33

Molecular Weight

2180.29

Quality Standard

98% up by HPLC, USP, cGMP, DMF

Appearance

white to off-white crystalline powder


COA of Bivalirudin


  Items

Specifications

Results

Appearance

White or almost white crystalline powder

White powder

Assay (by HPLC)

98%-102%

99.34%

Identification

Positive

Positive

Absorbance(E1cm)

465-495

482.5

Melting point

191C - 195C

93.5C-195C

Loss on drying

< 0.5%

0.19%

Specific rotation

+288-298

290.2

Residue on ignition

< 0.10%

0.03%

Related substances

Total related substances < 1.5%

< 1.3%

Single related substances < 0.5%

< 0.4%

Residue solvents

< 0.2%

0.10%

Heavy metals

< 20 ppm

< 10 ppm

Conclusion

Meet the specification of enterprise standard


Usage


Function of Bivalirudin

Bivalirudin is a synthetic anticoagulant. It is an analog of naturally occurring hirudin. It is a polypeptide composed of 20 amino acids. It can bind to thrombin with high affinity and specifically inhibit the activity of thrombin. The reaction catalyzed and induced by thrombin. Bivalirudin can not only bind to free thrombin in plasma, but also bind to thrombin linked to blood clots. This binding is reversible and does not require the presence of ATⅢ. Bivalirudin has a strong anticoagulant effect, and has antithrombotic effect on a variety of animal arterial and venous models. Bivalirudin can prolong partial thromboplastin time (APTT), thrombin time (PT) and activated clotting time (ACT).


Bivalirudin is suitable for patients with unstable angina and unstable angina pectoris undergoing PTCA; percutaneous intervention in acute ischemic coronary complications.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
Liraglutide 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
nonapeptide-1
Nonapeptide-1 158563-45-2
99% up by HPLC
Linaclotide
Linaclotide 851199-59-2
98% up, Medical Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact